Research Overview

Akebia’s licensed and internally developed intellectual property has enabled the company to become a leader in the development of HIF-PH (hypoxia inducible factor prolyl hydroxylase) inhibitors and the leading company working on human protein tyrosine phosphatase beta (HPTPβ) inhibitors targeting Angiopoietin-2.

AKB-6548 and AKB-4924 are two selective HIF-PH inhibitors that have been shown to have profound effects for anemia, wound healing and anti-microbial therapy. Akebia’s HPTPβ inhibitors modulate Angiopoietin-2 activity and represent an exciting new approach in the treatments for vascular leak, retinopathy, cancer and critical limb ischemia (CLI).